For the past decade, non–small cell lung cancer (NSCLC) exemplifies precision medicine with multiple oncogenic molecular alterations that serve as potential targets for therapy, such as epidermal growth factor receptor (EGFR) and ALK, yielding profound clinical benefits to certain cohorts of patients (1, 2). The gene discussed is ALK; the disease is non-small cell lung carcinoma.